Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Johnson & Johnson’s Multiple Sclerosis Treatment Drug Secures FDA Approval – Launching April 2021

By John F. Heerdink, Jr.

Reportedly, FDA has approved Johnson & Johnson’s (JNJ) Ponvory, as a daily oral drug to treat relapsing forms of multiple sclerosis MS. The drug is expected to launch in early April 2021, entering a market currently dominated by big names like Novartis’ Kesimpta, Roche’s Ocrevus, and Gilenya, and Biogen’s top-selling drug Tecfidera.

The FDA approved the drug, Ponvory based on study data from a two-year late-stage where Ponvory displayed higher efficacy in significantly reducing annual relapses by about 30% in comparison to Sanofi’s approved MS drug Aubagio. J&J’s Ponvory is a once-daily oral treatment, as opposed to Kesimpta, which is injected by patients at home, or even Ocrevus that is administered as an infusion in a clinic or hospital.  The drug has also surpassed Aubagio at reducing fatigue among patients. The approval brings a big cause of concern for Biogen, whose Tecfidera drug patent is expiring along with increasing competition in the MS landscape.

Ponvory is also under review by the European Medicines Agency.

Dow 30 component Johnson & Johnson (JNJ) is a worldwide healthcare-focused company that embraces research and science so that it can provide customers with innovative ideas, products, and services. To learn more about Johnson & Johnson (JNJ) and to continue to track its progress visit the Vista Partners Johnson & Johnson Coverage Page.

If you liked this story please consider, visiting the Atossa Therapeutics (ATOS) dedicated page at Vista Partners to learn about the Seattle-based biotech firm’s work towards finding therapeutic treatments for Breast Cancer and the Coronavirus. 

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive! Please join us at Vista Partners and receive our FREE email updates throughout the week and view our exclusive content and research.

(Read Original Story: U.S. FDA approves J&J's multiple sclerosis treatment; launch in April in Reuters)


Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Connect with us